MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 09-15-2025
Champions Oncology DPO Ratio 2011-2026 | CSBR
Annual DPO Ratio Champions Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.6 | 69.1 | 50.7 | 36.8 | 42.8 | 63.8 | 71.8 | 74.5 | 69.7 | 79.7 | 67.6 | 57.2 | 82.5 | 125 | 184 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 | 36.8 | 75.9 |
Quarterly DPO Ratio Champions Oncology
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.9 | - | 62 | 71.2 | - | 71 | 65.9 | - | 59.5 | 43.8 | 35 | - | 51.5 | 55.5 | 21.7 | - | 65 | 53.5 | 47 | 44.9 | 65.2 | 64.8 | 65 | 58 | 73.5 | 54.7 | 56.5 | 51.5 | - | 56.4 | 61.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.5 | 21.7 | 56.3 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.82 | -3.48 % | $ 4.47 M | China |
 |
Axsome Therapeutics
AXSM
|
529 | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
58.1 | $ 23.88 | - | $ 2.92 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Certara
CERT
|
7.85 | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
62.3 | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
148 | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Galapagos NV
GLPG
|
81.9 | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Codexis
CDXS
|
98.4 | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
24.8 | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
28.9 | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
4.92 | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Immuron Limited
IMRN
|
597 | $ 0.75 | -0.69 % | $ 6.43 M |  Australia |
 |
InMed Pharmaceuticals
INM
|
129 | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
Insmed Incorporated
INSM
|
227 | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
6.01 K | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
1.01 K | $ 29.11 | -0.31 % | $ 1.69 B | USA |